5 results on '"M.-H. Schlageter"'
Search Results
2. Percentage of free serum prostate-specific antigen: A new tool in the early diagnosis of prostatic cancer
- Author
-
F. Nivelon, A. Le Duc, C. Borschneck, Y. Najean, C. Role, Olivier Cussenot, M. Chiron, D. Rastel, M.-H. Schlageter, H. Francois, Pierre Teillac, François Desgrandchamps, Toubert Me, J. Guillet, and Paul Meria
- Subjects
Adult ,Male ,Cancer Research ,medicine.medical_specialty ,Pathology ,Time Factors ,Prostatic Hyperplasia ,Urology ,urologic and male genital diseases ,Diagnosis, Differential ,Antigen ,Reference Values ,Prostate ,Biomarkers, Tumor ,medicine ,Humans ,Aged ,Retrospective Studies ,Immunoradiometric assay ,medicine.diagnostic_test ,business.industry ,Prostatic Neoplasms ,Cancer ,Middle Aged ,Prostate-Specific Antigen ,Hyperplasia ,medicine.disease ,Prostate-specific antigen ,medicine.anatomical_structure ,ROC Curve ,Oncology ,Immunoassay ,Adenocarcinoma ,Immunoradiometric Assay ,business - Abstract
Prostate-specific antigen (PSA) is a protease able to bind to serum antiproteases as alpha 1 antichymotrypsin (ACT). Free PSA (FPSA) corresponds to the fraction of total PSA (TPSA) which is unbound to ACT. Specific detection of the FPSA seems to be a valuable tool in the distinction between prostatic cancer (PCa) and benign prostatic hyperplasia (BPH). Our aim was to evaluate retrospectively the FPSA/TPSA ratio in comparison to TPSA or FPSA determination, using two new immunoradiometric assays (PSA-RIACT and FPSA-RIACT, CIS bio international, Gif Sur Yvette, France) in the early diagnosis of PCa. 256 men, with TPSA levels between 0.7 and 44.7 ng/ml (median age = 69 years), including 164 sera obtained from patients with BPH and 92 sera from patients with untreated PCa were assayed. All diagnoses were histologically confirmed and patients tested before any adjuvant treatment. The evaluation of the median FPSA/TPSA ratio in the two groups showed significantly different values (BPH group: 24.2%, PCa group: 12.1%, P0.0001). By R.O.C. (Receiver-Operating-Characteristics) analysis, we show that the FPSA/TPSA ratio is the method of choice for discriminating BPH and PCa, since the area under curve is the greatest for the FPSA/TPSA ratio curve, as compared to the TPSA or FPSA curves (P0.0001). The best accuracy (number of true positive + true negative/total = 82.4%) was obtained with a FPSA/TPSA ratioor = 15% with high odds ratio (20.5; confidence interval (CI): 11.2; 37.7). Of interest, similar results were also confirmed even in the subpopulation with serum TPSA levels between 2.5 and 10 ng/ml (161 patients including 99 BPH and 62 PCa). We thus confirm that combined serum measurement of FPSA and TPSA is of particular interest in the early diagnosis of PCa for patients with non-suspicious digital rectal examination and a TPSA value between 2.5 and 10 ng/ml. In those patients, biopsy should be reserved to the cases with FPSA/TPSA below 15%, which allows significant odds ratio (12.8; CI: 5.2; 31.4). Otherwise, to avoid the risk of missing any PCa, usual follow-up with combined TPSA and FPSA determination would be required with the same criteria of biopsy (i.e. FPSA/TPSA ratioor = 15% when TPSA value is between 2.5 and 10 ng/ml; or TPSA10 ng/ml).
- Published
- 1996
3. Tumour-Associated Trypsin Inhibitor and Renal Cell Carcinoma
- Author
-
S. Bassi, M.-H. Schlageter, A. Le Duc, Paul Meria, François Desgrandchamps, T. Janssen, Ariane Cortesse, Toubert Me, Pierre Teillac, and Olivier Cussenot
- Subjects
Male ,medicine.medical_specialty ,Pathology ,Urology ,medicine.medical_treatment ,Radioimmunoassay ,Nephrectomy ,Sensitivity and Specificity ,Gastroenterology ,Metastasis ,Renal cell carcinoma ,Internal medicine ,Biomarkers, Tumor ,Carcinoma ,medicine ,Humans ,Carcinoma, Renal Cell ,Neoplasm Staging ,Retrospective Studies ,Kidney ,biology ,Epithelioma ,business.industry ,medicine.disease ,Kidney Neoplasms ,Ferritin ,medicine.anatomical_structure ,Trypsin Inhibitor, Kazal Pancreatic ,Creatinine ,biology.protein ,Female ,business - Abstract
In the absence of a specific marker for renal cell carcinoma (RCC), we evaluated the tumour-associated trypsin inhibitor (TATI) in patients with RCC. Between November 1990 and November 1993, 63 patients with RCC and 23 patients with benign renal disease underwent a competitive radioimmunoassay of TATI. The cutoff value was defined on a series of serum samples of 96 healthy subjects (normal n < 20 micrograms/l, then 25 micrograms/l after April 1993). We related the value of TATI to the tumour stage and compared the sensitivities of TATI and other markers (CEA, CA 15-3, CA 125, CA 19-9, ferritin). In 24 patients the TATI assay was repeated 3-12 months after radical nephrectomy. 15 patients with benign disease had a normal value of TATI (specificity: 65%). 44 of the 63 patients had a value of TATI above the cutoff point (sensitivity: 69%). Sensitivities of CEA, CA 15-3, CA 125, CA 19-9 and ferritin were 5, 10, 13, 5, 35%, respectively. The TATI value was correlated with the stage of the disease. Among the 15 patients without metastasis, the mean preoperative value was 112 micrograms/l (14-760) versus 46 micrograms/l (24-180) postoperatively. In the 9 patients with metastasis, the preoperative mean value was 100 micrograms/l (20-434) versus 240 micrograms/l (22-544) postoperatively. TATI showed a better sensitivity than other markers for RCC but its specificity is limited. Nevertheless it can be useful for a postoperative follow-up. TATI remains one of the best serum markers for RCC.
- Published
- 1995
4. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients
- Author
-
C. Corone, D. So, F. Tenenbaum, Serge Koscielny, C. Dejax, F. Bussière, Stéphane Bardet, J. J. Girard, Laurence Leenhardt, Massimo Torlontano, Martin Schlumberger, F. Archambeaud, Michel Toubeau, Ellen Benhamou, Françoise Borson-Chazot, David Taïeb, A. Hitzel, A. Prost, Claire Schvartz, Frédéric Troalen, M. H. Schlageter, J. L. Schlienger, Olivier Schneegans, I. Brenot-Rossi, Françoise Bonichon, Marcel Ricard, Olivier Morel, F. Claustrat, and M E Toubert
- Subjects
Adult ,Male ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Clinical Biochemistry ,Carcinoma, Papillary, Follicular ,Biochemistry ,Sensitivity and Specificity ,Thyroglobulin ,Iodine Radioisotopes ,Endocrinology ,Internal medicine ,medicine ,Carcinoma ,Humans ,Prospective Studies ,Thyroid Neoplasms ,Follicular thyroid cancer ,Prospective cohort study ,Radionuclide Imaging ,Thyroid cancer ,Thyroglobulin Measurement ,biology ,business.industry ,Biochemistry (medical) ,Remission Induction ,Thyroidectomy ,Middle Aged ,medicine.disease ,Chemistry, Clinical ,biology.protein ,Female ,Antibody ,Neoplasm Recurrence, Local ,business ,Biomarkers ,Follow-Up Studies - Abstract
Background: Serum thyroglobulin (Tg) is the marker of differentiated thyroid cancer after initial treatment and TSH stimulation increases its sensitivity for the diagnosis of recurrent disease. Aim: The goal of the study is to compare the diagnostic values of seven methods for serum Tg measurement for detecting recurrent disease both during L-T4 treatment and after TSH stimulation. Methods: Thyroid cancer patients who had no evidence of persistent disease after initial treatment (total thyroidectomy and radioiodine ablation) were studied at 3 months on L-T4 treatment (Tg1) and then at 9–12 months after withdrawal or recombinant human TSH stimulation (Tg2). Sera with anti-Tg antibodies or with an abnormal recovery test result were excluded from Tg analysis with the corresponding assay. The results of serum Tg determination were compared to the clinical status of the patient at the end of follow-up. Results: Thirty recurrences were detected among 944 patients. A control 131I total body scan had a low sensitivity, a low specificity, and a low clinical impact. Assuming a common cutoff for all Tg assays at 0.9 ng/ml, sensitivity ranged from 19–40% and 68–76% and specificity ranged from 92–97% and 81–91% for Tg 1 and Tg2, respectively. Using assays with a functional sensitivity at 0.2–0.3 ng/ml, sensitivity was 54–63% and specificity was 89% for Tg1. Using the two methods with a lowest functional sensitivity at 0.02 and 0.11 ng/ml resulted in a higher sensitivity for Tg1 (81% and 78%), but at the expense of a loss of specificity (42% and 63%); finally, for these two methods, using an optimized functional sensitivity according to receiver operating characteristic curves at 0.22 and 0.27 ng/ml resulted in a sensitivity at 65% and specificity at 85–87% for Tg1. Conclusion: Using an assay with a lower functional sensitivity may give an earlier indication of the presence of Tg in the serum on L-T4 treatment and may be used to study the trend in serum Tg without performing any TSH stimulation. Serum Tg determination obtained after TSH stimulation still permits a more reliable assessment of cure and patient’s reassurance.
- Published
- 2007
5. Use of Erythropoietin Radioimmunoassay in Polycythemias
- Author
-
M. E. Toubert, Najean Y, M. P. Podgorniak, and M. H. Schlageter
- Subjects
Cloning ,medicine.medical_specialty ,Kidney ,business.industry ,Erythroid progenitor ,Radioimmunoassay ,medicine.disease ,Endocrinology ,Polycythemia vera ,medicine.anatomical_structure ,Erythropoietin ,hemic and lymphatic diseases ,Internal medicine ,medicine ,business ,medicine.drug ,Polycythemias - Abstract
The recent production of erythropoietin (EPO) by cloning and expression of the human gene in mammalian cells has enabled, not only the treatment of severe anemias due to a defect in EPO production by the kidney, but also the development of sensitive immunoassays (Erslev et al. 1987) which allow large-scale study of EPO levels in human disorders.
- Published
- 1992
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.